Votrient Tablet, Film Coated
Product Images NDC 0078-1077

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Votrient (NDC 0078-1077). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Votrient 01

Votrient 200 mg film-coated tablets packaging label showing the brand name Votrient with generic name pazopanib. The label indicates a quantity of 120 tablets, prescription only, with storage instructions and manufacturer information for Novartis Pharmaceuticals Corporation. The label also mentions to refer to the Medication Guide.*

FDA Label Image

The Following Chemical Structure For Votrient (pazopanib) Is A Tyrosine Kinase Inhibitor (tki). Pazopanib Is Presented As The Hydrochloride Salt, With The Chemical Name 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide Monohydrochloride. It Has The Molecular Formula C21h23n7o2s•hcl And A Molecular Weight Of 473.99. (Votrient 02)

Chemical structure of pazopanib hydrochloride, the active ingredient in VOTRIENT 200 mg oral film-coated tablets by Novartis Pharmaceuticals Corporation. The diagram shows the molecular arrangement of atoms and bonds within the compound.*

FDA Label Image

Figure 1. Kaplan-meier Curve For Progression-free Survival In Rcc By Independent Assessment For The Overall Population (treatment-naïve And Cytokine Pre-treated Populations) (Votrient 03)

A Kaplan-Meier survival curve comparing progression-free proportions over 20 months between VOTRIENT (pazopanib hydrochloride) and placebo groups. The chart plots proportion progression-free on the y-axis against months on the x-axis, showing higher progression-free survival for VOTRIENT with median 9.2 months versus 4.2 months for placebo.*

FDA Label Image

Figure 2. Kaplan-meier Curve For Progression-free Survival In Sts By Independent Assessment For The Overall Population (Votrient 04)

A Kaplan-Meier curve comparing progression-free survival between VOTRIENT (pazopanib hydrochloride) and placebo groups. The y-axis represents the proportion of patients progression-free, and the x-axis shows time in months, with median progression-free survival of 4.6 months for VOTRIENT versus 1.6 months for placebo. Hazard ratio, confidence interval, and p-value are also noted.*

FDA Label Image

Principal Display Panelndc 0078-0670-66votrient(pazopanlb)tablets200 mg120 Tabletsrx Only (Votrient 05)

Votrient 200 mg film-coated tablets package label for oral use by Novartis Pharmaceuticals Corporation. The label states each tablet contains 216.7 mg of pazopanib hydrochloride equivalent to 200 mg pazopanib free base. It includes storage instructions, a note on dosage instructions referring to accompanying prescribing information, and displays the 120 tablets count with Rx only indication. The product is noted to be manufactured in Spain and distributed from New Jersey, USA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.